轉錄作用調控DNA 損壞訊息路徑活化之探討

Transcription-mediated activation of DNA damage signaling pathway

黃鼎翔(Ting-Hsiang Huang)

指導教授 ： 李財坤

國立臺灣大學/醫學院/微生物學研究所/碩士(2005年)

https://doi.org/10.6342/NTU.2005.00603

摘要

第一型去氧核糖核酸拓蹼異構酶(DNA topoisomerase I)目標藥物，喜樹鹼(camptothecin)，為一種針對複製期細胞特性的抗癌藥物。目前對細胞經抗癌藥物camptothecin 處理所引起之細胞反應仍未明瞭。近來研究陸續顯示，在高濃度camptothecin 處理下，對非複製期與不具週期性的細胞造成毒殺作用，而camptothecin 亦能引起與複製無關的細胞反應，例如: 轉錄作用(transcription)引發之topoisomerase I-DNA 可切性複合體(cleavable complex)遭蛋白解體(proteasome)程序降解(degradation)。本篇論文指出，由camptothecin 對細胞所誘發的DNA 損壞訊息(DNA damage signals)，例如: ATM 蛋白的自體磷酸化(autophosphorylation)，細胞週期有關的Chk2蛋白與腫瘤抑制蛋白p53 的磷酸化現象，在處以藥物抑制細胞轉錄作用後(阻礙topoisomerase I-DNA 可切性複合體降解)，能降低蛋白磷酸化程度。此外，利用蛋白解體抑制劑亦能減少由camptothecin 引起DNA 損壞訊息活化程度，達到與細胞轉錄作用抑制劑雷同的效果。綜合上述實驗結果，我們推論: 轉錄作用引發之topoisomerase I-DNA 可切性複合體遭蛋白解體程序降解能有效暴露DNA 斷點(DNA breaks)。本篇論文顯示，RNA 聚合酶(RNA polymerase)與topoisomerase I-DNA 可切性複合物之間的撞擊，與伴隨而來的可切性複合體遭蛋白解體降解，在camptothecin所引起非複製期細胞之細胞反應與毒害效果上，扮演不可或缺的決定性角色。

關鍵字

拓蹼異構酶轉錄作用 ； 喜樹鹼 ； 可切性複合體

並列摘要

Camptothecin, a DNA topoisomerase I-targeting drug, has been suggested to be a S-phase specific anticancer drug. However, the cellular responses to camptothecin remain largely unclear. Recent studies indicated that the high concentration of camptothecin could kill the non-S phase and non-cycling cells. In addition, camptothecin also induces the replication-independent cellular responses, such as the transcription- and proteasome-dependent degradation of topoisomerase I-DNA cleavable complexes. In this thesis, we showed that inhibition of RNA transcription, thereby blocking topoisomerase I-DNA cleavable complexes degradation, prevented various camptothecin-induced DNA damage signals, e.g. ATM autophosphorylation, phosphorylation of Chk2 and p53 activation. Proteasome inhibitors also prevented the activation of camptothecin-induced signaling pathways like transcription inhibitors did. Taken together, our results indicate that the transcription- dependent and proteasome-mediated degradation of topoisomerase I-DNA cleavable complexes removes topoisomerase I away from DNA damage and thereby exposes DNA breaks. Our results suggest a novel pathway in which the collision between RNA polymerase and cleavable complexes coupled with subsequent proteasomal degradation of topoisomerase-DNA cleavable complexes play essential roles in determining cellular responses and cytotoxicity of camptothecin in the non-S phase cells.

並列關鍵字

topoisomerase I ； ATM ； cleavable complex ； transcription ； proteasome

參考文獻

Adams, J. (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell, 5, 417-421.

Andoh, T., Ishii, K., Suzuki, Y., Ikegami, Y., Kusunoki, Y., Takemoto, Y. and Okada, K. (1987) Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci U S A, 84, 5565-5569.

Bakkenist, C.J. and Kastan, M.B. (2003) DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature, 421, 499-506.

Balajee, A.S. and Geard, C.R. (2004) Replication protein A and gamma-H2AX foci assembly is triggered by cellular response to DNA double-strand breaks. Exp Cell Res, 300, 320-334.

Barrows, L.R., Holden, J.A., Anderson, M. and D'Arpa, P. (1998) The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication. Mutat Res, 408, 103-110.